舒格利单抗在实体瘤或淋巴瘤患者中的群体药代动力学模型
本研究基于9项I-III期研究、1628例受试者的汇总数据,采用非线性混合效应模型建立舒格利单抗的群体药代动力学模型,评估人口学、肝肾功能、抗药抗体、肿瘤负荷等协变量对暴露的影响。最终模型为二室模型、一级消除、清除率随时间变化;体重、白蛋白、性别、ADA、肿瘤负荷和肿瘤类型与清除率显著相关,但所有显著协变量对暴露的影响均小于20%,结论为无需剂量调整。
要点
- 舒格利单抗PopPK模型为二室模型、一级消除、清除率随时间变化。
- 体重、白蛋白、性别、ADA、肿瘤负荷和肿瘤类型与清除率显著相关。
- 所有显著协变量对暴露的影响均小于20%,无需剂量调整。
核心结论
- PopPK模型充分描述了舒格利单抗的药代动力学特征,所有协变量对暴露无临床意义影响,无需剂量调整。
研究设计与样本
- 基于9项I-III期研究、1628例受试者的汇总数据,采用非线性混合效应模型建立舒格利单抗PopPK模型。
主要发现
- 最终模型为二室模型、一级消除、清除率随时间变化。
- 清除率与体重、白蛋白、性别、ADA、肿瘤负荷和肿瘤类型显著相关。
- 中央室容积与体重、白蛋白、性别和肿瘤类型显著相关。
- 年龄、种族、丙氨酸氨基转移酶、天冬氨酸氨基转移酶、肌酐、总胆红素、碱性磷酸酶、联合治疗、肌酐清除率、ECOG、肾功能或肝功能与模型无显著关系。
- 所有显著协变量对舒格利单抗暴露的影响均小于20%。
临床怎么用
- 基于当前PopPK分析,舒格利单抗在不同协变量亚组中无需进行剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to develop a population pharmacokinetics model for sugemalimab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), using data from Phase I-III trials and to assess clinical factors affecting sugemalimab exposure. METHODS: A nonlinear mixed-effect modelling approach was employed to analyse pooled data from nine studies involving 1628 subjects to characterize the PopPK of sugemalimab. This investigation examined the influence of various covariates on sugemalimab pharmacokinetics (PK), encompassing demographics, baseline hepatic and renal function-related covariates, and others (including anti-drug antibody [ADA], combination treatment, Eastern Cooperative Oncology Group [ECOG] performance score, tumour burden and tumour type). Estimation accuracy and predictive ability of the final model were evaluated using various methods. The influence of covariates on sugemalimab exposure was assessed by simulation from the final model. RESULTS: A two-compartment model with first-order elimination and time-varying clearance effectively described the PK of sugemalimab. Covariate analyses revealed significant relationships between sugemalimab clearance and body weight, albumin, gender, ADA, tumour burden and tumour type. The statistically significant covariates on central volume were body weight, albumin, gender and tumour type. No significant relationships were found in the final model for age, race, alanine aminotransferase, aspartate aminotransferase, creatinine, total bilirubin, alkaline phosphatase, combination treatment, creatinine clearance, ECOG, renal function or hepatic function. All significant covariates demonstrated less than a 20% effect on sugemalimab exposure. CONCLUSIONS: The PopPK model adequately described the pharmacokinetic profile of sugemalimab with no clinically meaningful impact observed on its exposure across all covariates. Dose adjustment does not appear to be necessary.
引用
- Wang K, Pan C, Xu F, et al. Comprehensive population pharmacokinetic modelling of sugemalimab, an anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I-III studies. Br J Clin Pharmacol. 2024. PMID: 39389094. doi:10.1111/bcp.16276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。